Safety and Efficacy of "Immuncell-LC" in TACE Therapy

Phase 2 Completed 76 enrolled GC Cell Corporation

RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of 'Immuncell-LC group' and 'non-treatment group' in the patients undergone Transarterial Chemoembolization for intermediate stage hepatocellular carcinoma

Timeline

Start: 2018-05-28
Primary completion: 2020-08-11
Completion: 2022-09-22

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Immuncell-LC	Cell therapy	200 ml	Intravenous

Safety and Efficacy of "Immuncell-LC" in TACE Therapy

Summary

Timeline

Drugs

Indications